Navigation Links
Bisexuality not a transitional phase among women, according to new research
Date:1/15/2008

WASHINGTON -- Bisexuality in women appears to be a distinctive sexual orientation and not an experimental or transitional stage that some women adopt "on their way" to lesbianism, according to new research published by the American Psychological Association.

The study of 79 non-heterosexual women over 10 years found that bisexual women maintained a stable pattern of attraction to both sexes. In addition, the research appears to have debunked the stereotype that bisexual women are uninterested in or unable to commit to long-term monogamous relationships.

"This research provides the first empirical examination of competing assumptions about the nature of bisexuality, both as a sexual identity label and as a pattern of nonexclusive sexual attraction and behavior," wrote University of Utah psychologist Lisa M. Diamond, PhD, who conducted the study. "The findings demonstrate considerable fluidity in bisexual, unlabeled and lesbian women's attractions, behaviors and identities and contribute to researchers' understanding of the complexity of sexual-minority development over the life span."

Results of the research were published in the January issue of Developmental Psychology, published by the APA. This special issue of the journal focuses on research into psychological topics concerning sexual orientation and gender identity.

Diamond used interview data collected five times over a decade from 79 women who identified as lesbian, bisexual or unlabeled. The subjects initially ranged in age from 18 to 25 years old.

Among Diamond's findings:

  • Bisexual and unlabeled women were more likely than lesbians to change their identity over the course of the study, but they tended to switch between bisexual and unlabeled rather than to settle on lesbian or heterosexual as their identities.

  • Seventeen percent of respondents switched from a bisexual or unlabeled identity to heterosexual during the study -- but more than half of these women switched back to bisexual or unlabeled by the end.

  • By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.

  • Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.

"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.


'/>"/>

Contact: Pam Willenz
pwillenz@apa.org
202-336-5707
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Seabrook House Opens Transitional Living Facility: Seabrook West
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. Cytopia Commences Phase II Cancer Drug Study
6. QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy
7. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
8. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
9. Early Phase II results show bosutinib safe, effective for CML
10. CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA
11. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated ... latest FDA requirements, which stipulates new criteria regarding medical device manufacture ... Medical ID jewelry such as Medical ID Bracelets, can rest assured ... of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process ...
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
Breaking Medicine Technology: